Enrofloxacin Shifts Intestinal Microbiota and Metabolic Profiling and Hinders Recovery from Salmonella enterica subsp. enterica Serovar Typhimurium Infection in Neonatal Chickens

Boheng Ma, Xueran Mei, Changwei Lei, Li Cui, Yufeng Gao, Linghan Kong, Xiwen Zhai, Hongning WangmSphere 2020 · DOI

TL;DR

This study reveals that enrofloxacin, a common antibiotic in poultry, disrupts the chicken gut microbiome and metabolome, paradoxically making them more susceptible to Salmonella infection and hindering recovery. This highlights a critical trade-off in antibiotic use, where intended therapeutic benefits may be undermined by unintended consequences on host defense.

What Problem Does This Paper Address?

Salmonella infections are a significant global food safety concern, particularly in poultry, leading to substantial economic losses and public health risks. Antibiotics like enrofloxacin are widely used in poultry for both prevention and treatment of such infections. However, there's growing concern that antibiotic use can disrupt the delicate balance of the gut microbiome, potentially reducing the host's natural resistance to pathogens. This paper investigates how enrofloxacin, at different concentrations, affects the chicken gut's microbial community and its metabolic output, and how these changes influence susceptibility to and recovery from Salmonella enterica serovar Typhimurium (S. Typhimurium) infection. The core problem is understanding the complex interplay between antibiotic administration, the gut microbiome, host metabolism, and pathogen colonization, especially in the context of preventing and managing Salmonella outbreaks in poultry.

Methods

The researchers employed a multi-omics approach to dissect the effects of enrofloxacin and S. Typhimurium infection.

  • Animal Model: One-day-old chickens were divided into groups and administered varying concentrations of enrofloxacin (including a control group receiving only water) for five days. Subsequently, three of these groups were challenged with S. Typhimurium, while the control groups received a placebo.
  • Bacterial Enumeration: S. Typhimurium levels were quantified in cecal contents, heart, liver, and spleen at different time points (days 7, 14, and 21) using bacterial counting (log10 CFU/g).
  • Microbial Community Analysis: 16S rRNA gene sequencing was performed on cecal contents to analyze the diversity and composition of the gut microbial community. This allowed for the identification of changes in bacterial phyla and genera.
  • Metabolomic Profiling: Untargeted metabolomics was used to identify and quantify metabolites present in the cecal contents at day 14. This provided insights into the metabolic state of the gut.
  • Multi-omics Integration: Correlation analyses were conducted to link microbial community structures with metabolic profiles, aiming to identify key microbes and metabolites associated with S. Typhimurium colonization and host response. Linear discriminant analysis (LDA) effect size (LEfSe) was used to identify microbial biomarkers differentiating the experimental groups.

Datasets

The study utilized samples from experimentally infected and treated chickens. No new public datasets were introduced or used for benchmarking in this paper. The primary data generated were from:

  • Cecal contents, heart, liver, and spleen samples from chickens at 7, 14, and 21 days of age.
  • 16S rRNA gene sequencing data from cecal contents.
  • Untargeted metabolomics data from cecal contents.

Key Insights and Ideas

  • Antibiotic-Induced Susceptibility: The most striking finding is that enrofloxacin treatment, rather than preventing Salmonella infection, actually increases the susceptibility of chickens to S. Typhimurium colonization and significantly hinders their recovery. This suggests that enrofloxacin disrupts the gut's natural defense mechanisms.
  • Microbiome Disruption and Pathogen Persistence: Enrofloxacin treatment led to significant alterations in the gut microbial community structure. This dysbiosis, characterized by shifts in dominant bacterial phyla and genera, created an environment where S. Typhimurium could not only colonize more readily but also persist for longer periods.
  • Metabolic Rewiring: The study revealed that enrofloxacin and S. Typhimurium infection profoundly altered the metabolic landscape of the chicken cecum. These metabolic shifts likely play a crucial role in either promoting pathogen growth or impairing the host's ability to clear the infection.
  • Specific Microbial Players: Certain bacteria, like Faecalibacterium and Anaerostipes, were identified as being closely linked to the chicken intestinal metabolome and were screened using multi-omics. Changes in the abundance of specific genera, such as Lactobacillus, were observed over time and across treatment groups, hinting at their potential roles in host defense or pathogen interaction.
  • Complex Interactions: The multi-omics approach highlighted intricate correlations between microbial communities and metabolic pathways. For instance, Verrucomicrobia's positive correlation with fatty acid biosynthesis and the gut immune network suggests its potential role in host defense, which might be indirectly affected by enrofloxacin.

Key Results

  • Increased S. Typhimurium Abundance: Enrofloxacin-treated groups (E2 and E3) showed significantly higher S. Typhimurium abundance in cecal contents compared to the untreated control group (E1) at multiple time points, particularly on day 7 and day 14.
  • Prolonged Pathogen Persistence: S. Typhimurium persisted longer in enrofloxacin-treated chickens, with higher relative abundances observed on day 21 in groups E2 and E3 compared to E1.
  • Altered Microbial Diversity: At day 7, the enrofloxacin-treated groups exhibited different alpha-diversity profiles, with the high-dose group (E3) showing the highest diversity and the low-dose group (E1) the lowest. However, by day 21, the low-dose group (E1) showed the highest diversity, while the high-dose group (E3) showed the lowest.
  • Shifts in Dominant Bacteria: The study observed a decrease in Proteobacteria and Firmicutes and an increase in Bacteroidetes with gut maturation. Specific genera like Faecalibacterium, Bacteroides, and Escherichia were correlated with various metabolites.
  • Metabolic Pathway Enrichment: Differential metabolites were enriched in pathways related to short-chain fatty acid (SCFA) metabolism, amino acid metabolism, and unsaturated fatty acid biosynthesis, indicating broad metabolic disruption.

Limitations and Future Work

  • Dosage-Dependent Effects: While the study explored different enrofloxacin concentrations, the precise mechanisms by which each dose impacts the microbiome and host response require further investigation.
  • Causality of Metabolic Changes: While correlations between microbial shifts and metabolic changes were identified, establishing direct causal links and understanding the functional consequences of these metabolic alterations for S. Typhimurium colonization requires more in-depth research.
  • Specific Mechanisms of Resistance: The study suggests that enrofloxacin hinders recovery, but the specific molecular mechanisms by which the altered microbiome and metabolome contribute to this impaired recovery are not fully elucidated.
  • Future Directions: The authors suggest further studies to explore the effects of administering specific metabolites, such as $\alpha$-linolenic acid, on S. Typhimurium colonization. Additionally, investigating the role of IgA production by Verrucomicrobia in the context of enrofloxacin treatment and S. Typhimurium infection is proposed. The findings also emphasize the need for more careful and rational use of antibiotics in poultry to mitigate such unintended consequences.

Summary updated

Abstract

Enrofloxacin is an important antibiotic used for prevention and treatment of <i>Salmonella</i> infection in poultry in many countries. However, oral administration of enrofloxacin may lead to the alterations in the microbiota and metabolome in the chicken intestine, thereby reducing colonization resistance to the <i>Salmonella</i> infection. To study the effect of enrofloxacin on <i>Salmonella</i> in the chicken cecum, we used different concentrations of enrofloxacin to feed 1-day-old chickens, followed by oral challenge with <i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium (<i>S.</i> Typhimurium). We then explored the distribution pattern of <i>S.</i> Typhimurium in cecum contents <i>in vivo</i> and analyzed the microbial community structure of cecum contents using microbial 16S amplicon sequencing. Untargeted metabolomics was used to explore the gut metabolome on day 14. <i>Faecalibacterium</i> and <i>Anaerostipes</i>, which are closely related to the chicken intestinal metabolome, were screened using a multi-omics technique. The abundance of <i>S.</i> Typhimurium was significantly higher in the enrofloxacin-treated group than in the untreated group, and <i>S.</i> Typhimurium persisted longer. Moreover, the cecal colony structures of the three groups exhibited different characteristics, with <i>Lactobacillus</i> reaching its highest abundance on day 21. Notably, <i>S.</i> Typhimurium infection is known to affect the fecal metabolome of chickens differently. Thus, our results suggested that enrofloxacin and <i>Salmonella</i> infections completely altered the intestinal microbiota and metabolism of chickens.<b>IMPORTANCE</b> In this study, we examined the effects of <i>S.</i> Typhimurium infection and enrofloxacin treatment on the microbiota and metabolite synthesis in chicken cecum, in order to identify target metabolites that may promote <i>S.</i> Typhimurium colonization and aggravate inflammation and to evaluate the important microbiota that may be associated with these metabolites. Our findings may facilitate the use of antibiotics to prevent <i>S.</i> Typhimurium infection.
BibTeX
@inproceedings{ma2020enrofloxacin,
  author = {Boheng Ma and Xueran Mei and Changwei Lei and Li Cui and Yufeng Gao and Linghan Kong and Xiwen Zhai and Hongning Wang},
  title = {{Enrofloxacin Shifts Intestinal Microbiota and Metabolic Profiling and Hinders Recovery from Salmonella enterica subsp. <i>enterica</i> Serovar Typhimurium Infection in Neonatal Chickens}},
  booktitle = {mSphere},
  year = {2020},
  doi = {10.1128/msphere.00725-20},
}
Figure